Oxford BioMedica plc -4.6% potential downside indicated by Numis

Oxford BioMedica plc with ticker (LON:OXB) now has a potential downside of -4.6% according to Numis.



Numis set a target price of 180 GBX for the company, which when compared to the Oxford BioMedica plc share price of 189 GBX at opening today (22/03/2024) indicates a potential downside of -4.6%. Trading has ranged between 164 (52 week low) and 475 (52 week high) with an average of 335,063 shares exchanging hands daily. The market capitalisation at the time of writing is £190,298,883.

Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.